Terms ending in 2028

Array Biopharma Inc.

Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.

Patent	Title	Holder	Status	Expires	Confidence
US 8,026,233	P38 Inhibitors and Methods of Use Thereof Array Biopharma, Inc. In force Term ends Jan 5, 2028 · High confidence	Array Biopharma, Inc.	In force	Term ends Jan 5, 2028	High confidence
US 8,853,199	Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors Genentech, Inc. In force Term ends Mar 7, 2028 · High confidence	Genentech, Inc.	In force	Term ends Mar 7, 2028	High confidence
US 7,598,383	Heterocyclic Inhibitors of Mek and Methods of Use Thereof Array Biopharma Inc. In force Term ends Jun 12, 2028 · High confidence	Array Biopharma Inc.	In force	Term ends Jun 12, 2028	High confidence
US 9,156,795	Novel Hydrogen Sulfate Salt Alexion Pharma International Operations Limited In force Ends no later than Jun 23, 2028 · Medium confidence	Alexion Pharma International Operations Limited	In force	Ends no later than Jun 23, 2028	Medium confidence
US 8,846,683	Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors Genentech, Inc. In force Term ends Jul 3, 2028 · High confidence	Genentech, Inc.	In force	Term ends Jul 3, 2028	High confidence
US 9,409,886	Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors Genentech, Inc. In force Term ends Jul 3, 2028 · High confidence	Genentech, Inc.	In force	Term ends Jul 3, 2028	High confidence
US 8,003,662	Heterobicyclic Thiophene Compounds and Methods of Use Array Biopharma, Inc. In force Term ends Aug 28, 2028 · High confidence	Array Biopharma, Inc.	In force	Term ends Aug 28, 2028	High confidence

7 of 7 patents shown. Soonest term end first, then patent number.

3 of these are in force and held by Array Biopharma Inc..

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.